Insights into the change in brain natriuretic peptide after ST-elevation myocardial infarction (STEMI): Why should it be better than baseline?

Canadian Journal of Physiology and Pharmacology

Volumn 85, Issue 1, 2007, Pages 173-178

  Ezekowitz, Justin A ^a   Théroux, Pierre ^b   Welsh, Robert ^a   Bata, Iqbal ^c   Webb, John ^d   Armstrong, Paul W ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b MONTREAL HEART INSTITUTE   (Canada)

^c DALHOUSIE UNIVERSITY   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Clinical trial; Myocardial infarction; Natriuretic peptides

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CREATINE KINASE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; FIBRINOLYTIC AGENT; PEPTIDE FRAGMENT; PRO BRAIN NATRIURETIC PEPTIDE (1 76); PRO-BRAIN NATRIURETIC PEPTIDE (1-76); TENECTEPLASE; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; CONTROLLED STUDY; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; REPERFUSION; ST SEGMENT ELEVATION; AGED; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY BLOOD FLOW; FEMALE; HEART MUSCLE REPERFUSION; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PREDICTION AND FORECASTING; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK; RISK ASSESSMENT; TIME; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CORONARY CIRCULATION; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; NATRIURETIC PEPTIDE, BRAIN; ODDS RATIO; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RESEARCH DESIGN; RISK ASSESSMENT; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 34250888871     PISSN: 00084212     EISSN: None     Source Type: Journal    
DOI: 10.1139/Y06-102     Document Type: Article

References (16)

1. Anderson, W.D., Wagner, N.B., Lee, K.L., White, R.D., Yuschak, J., Behar, V.S., et al. 1988. Evaluation of a QRS scoring system for estimating myocardial infarct size. VI: Identification of screening criteria for non-acute myocardial infarcts. Am. J. Cardiol. 61: 729-733. doi:10.1016/0002-9149(88)91056-9.
2. Antman, E.M., Anbe, D.T., Armstrong, P.W., Bates, E.R., Green, L.A., Hand, M., et al. 2004. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; A report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). J. Am. Coll. Cardiol. 44: E1-E211. doi:10.1016/j.jacc.2004.07.014.
3. Armstrong, P.W., and WEST Steering Committee. 2006. A comparison of pharmacologic therapy with/without timely coronary intervention vs. primary percutaneous intervention early after ST-elevation myocardial infarction: the WEST (Which Early ST-elevation myocardial infarction Therapy) study. Eur. Heart J. 27: 1530-1538. doi:10.1093/eurheartj/ eh1088.
4. Cochet, A., Zeller, M., Cottin, Y., Robert-Valla, C., Lalande, A., L'Huilllier, I., et al. 2004. The extent of myocardial damage assessed by contrast-enhanced MRI is a major determinant of N-BNP concentration after myocardial infarction. Eur. J. Heart Fail. 6: 555-560.
5. Ezekowitz, J.A., Theroux, P., Chang, W., Mahaffey, K.W., Granger, C.B., Weaver, W.D., Hochman, J.S., and Armstrong, P.W. 2006. N-terminal pro-brain natriuretic peptide and the timing, extent and mortality in ST elevation myocardial infarction. Can. J. Cardiol. 22: 393-397.
6. Gershlick, A.H., Stephens-Lloyd, A., Hughes, S., Abrams, K.R., Stevens, S.E., Uren, N.G., et al., and REACT Trial Investigators. 2005. Rescue angioplasty after failed thrombolytic therapy for acute myocardial infarction. N. Engl. J. Med. 353: 2758-2768. doi:10.1056/NEJMoa050849.
7. Inoue, T., Sakuma, M., Yaguchi, I., Mizoguchi, K., Uchida, T., Takayanagi, K., Hayashi, T., and Morooka, S. 2002. Early recanalization and plasma brain natriuretic peptide as an indicator of left ventricular function after acute myocardial infarction. Am. Heart J. 143: 790-796. doi:10.1067/mhj.2002.122170.
8. James, S.K., Lindahl, B., Siegbahn, A., Stridsberg, M., Venge, P., Armstrong, P., et al. 2003. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a global utilization of strategies to open occluded arteries (GUSTO)-IV substudy. Circulation, 108: 275-281. doi:10.1161/01.CIR.0000079170.10579.DC.
9. Mega, J.L., Morrow, D.A., de Lemos, J.A., Sabatine, M.S., Murphy, S.A., Rifai, N., et al. 2004. B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudy. J. Am. Coll. Cardiol. 44: 335-339. doi:10.1016/j.jacc.2004.04. 033.
10. Ndrepepa, G., Braun, S., Mehilli, J., von Beckerath, N., Nekolla, S., Vogt, W., et al. 2006. N-terminal pro-brain natriuretic peptide on admission in patients with acute myocardial infarction and correlation with scintigraphic infarct size, efficacy of reperfusion, and prognosis. Am. J. Cardiol. 97: 1151-1156. doi:10. 1016/j.amjcard.2005.11.029.
11. Richards, A.M., Nicholls, M.G., Yandle, T.G., Frampton, C., Espiner, E.A., Turner, J.G., et al. 1998. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation, 97: 1921-1929.
12. Richards, A.M., Nicholls, M.G., Espiner, E.A., Lainchbury, J.G., Troughton, R.W., Elliott, J., et al. 2003. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation, 107: 2786-2792. doi:10.1161/01.CIR. 0000070953.76250.B9.
13. Schroder, R., Wegscheider, K., Schroder, K., Dissmann, R., and Meyer-Sabellek, W. 1995. Extent of early ST segment elevation resolution: a strong predictor of outcome in patients with acute myocardial infarction and a sensitive measure to compare thrombolytic regimens. A substudy of the International Joint Efficacy Comparison of Thrombolytics (INJECT) trial. J. Am. Coll. Cardiol. 26: 1657-1664. doi:10.1016/0735-1097(95) 00372-X.
14. Talwar, S., Squire, I.B., Downie, P.F., Mccullough, A.M., Campton, M.C., Davies, J.E., Barnett, D.B., and Ng, L.L. 2000. Profile of plasma N-terminal proBNP following acute myocardial infarction; correlation with left ventricular systolic dysfunction. Eur. Heart J. 21: 1514-1521. doi:10.1053/euhj.1999. 2045.
15. Tapanainen, J.M., Lindgren, K.S., Makikallio, T.H., Vuolteenaho, O., Leppaluoto, J., and Huikuri, H.V. 2004. Natriuretic peptides as predictors of non-sudden and sudden cardiac death after acute myocardial infarction in the beta-blocking era. J. Am. Coll. Cardiol. 43: 757-763. doi:10.1016/j.jacc.2003.09.048.
16. Theroux, P., Armstrong, P.W., Mahaffey, K.W., Hochman, J.S., Malloy, K.J., Rollins, S., et al. 2005. Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial. Eur. Heart J. 26: 1964-1970. doi:10.1093/ eurheartj/ehi292.